CTOs on the Move


 
Nanōmix is the leader in mobile point-of-care diagnostics for use where time and accuracy is critical.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.nanomixdx.com
  • 2121, Williams Street
    San Leandro, CA USA 94577
  • Phone: 510.428.5300

Executives

Name Title Contact Details

Similar Companies

HospiScript Services

HospiScript Services, LLC is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

harro hofliger

harro hofliger is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Attain ABA

Attain ABA Therapy provides quality ABA therapy to children with autism. Our experienced BCBAs will create a customized treatment plan tailored to YOUR childs needs. Enroll Today!

Martin Bionics

A paradigm shift in prosthetic comfort and quality of life. The Socket-less Socket™ fits like a sneaker providing comfort and control for all amputation levels.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.